Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (January 2018)
15 slides from Staar Surgical's investor presentation, Jan 8, 2018
Slide 1: A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction
A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction Investor Update NASDAQ : STAA January 8, 2018 Evolution in Visual Freedom ™ 1
Slide 2: Forward-Looking Statements
™ BUILDING A FOUNDATION FOR CONSISTENT GROWTH F ORWARD - L OOKING S TATEMENTS All statements in this presentation that are not statements of historical fact are forward - looking statements, including statements about any of the following : any projections of earnings, revenue, sales, profit margins
Slide 3: A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses
™ BUILDING A FOUNDATION FOR CONSISTENT GROWTH A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction FY16 percent of lens revenue; STAAR also sells injectors that were 4% of total FY16 revenue; the ICL with central port is not available in the U
Slide 4: ICL - The Collamer Material Advantage
™ BUILDING A FOUNDATION FOR CONSISTENT GROWTH ICL™ - THE COLLAMER MATERIAL ADVANTAGE • Biocompatible • Offers UV protection • Quiet in the eye - A layer of fibronectin is believed to form around the lens, inhibiting white cell adhesion to the lens. This coating may prevent the lens from being identi
Slide 5: ICL Patient Testimonials
™ ICL™ PATIENT TESTIMONIALS: “ Upgradeable” “Reversible” We invite you to visit staar.com, discoverevo.com and discovericl.com
Slide 6: 10-Year Total Revenue & ICL Unit Growth
™ ™ $35.6M $49.8M $51.1M $55.0M $62.8M $63.8M $72.2M $75.0M $77.1M $82.4M 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Revenue 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 ICL Units GLOBAL LEADER IN PHAKIC IOL “ICL” IMPLANTATION CAGR: 10% T OTAL R EVENUE ; 15% ICL U NITS 10 - Year Total Re
Slide 7: Myopia: A Growing Global Concern
™ MYOPIA A Growing Global Concern… High Myopia Could Impact Almost 1.0 Billion People by 2050… • An inability to focus at distance due to genetic and/or environmental factors • Researchers expect dramatic increase in myopia ▪ More screen use; near vision work; and less time spent outdoors ▪ Positive
Slide 8: Presbyopia: A New Refractive Market Opportunity
™ PRESBYOPIA A New Refractive Market Opportunity Impacts 1.7 Billion People Globally… • An age - related loss of lens accommodation ▪ First symptoms generally appear at age 42 to 44 ▪ An inability to focus when reading • Surgical refractive options: Monocular/LASIK/RLE • An ICL refractive solution c
Slide 9: STAAR Surgical Results: Key Takeaways, 9 Months Ended September 29, 2017
™ Key Takeaways • Net Sales of $65.8 Million Up 9% from the Prior Year Period • ICL Sales Up 15% and Units Up 15% from the Prior Year Period • IOL Sales Down 13% from the Prior Year Period • Net Income of $1.2 Million Compared to a Net Loss of $1.8 Million in the Prior Year Period • Cash Provided by
Slide 10: STAAR's Current & Future Positioning
™ ™ » STAAR is the market leader and best refractive surgical solution and patient experience for high Myopia . » STAAR is focused on becoming a leading provider of refractive surgical solution and patient experience for mid - Myopia . » STAAR aims to become a market leader in refractive surgical so
Slide 11: 2018 Strategic Priorities
™ ™ » Achieve and Retain Compliance with All Regulatory Bodies – Culture of Quality » Successfully Build the Visual Freedom Market for Implantable Lenses: Tangibly Impact Surgeon Engagement, Practice Development and Patient Desirability » Execute Go - to - Market Strategy to Significantly Expand Mar
Slide 12: 2018 Financial Outlook
™ ™ 2018 FINANCIAL OUTLOOK » REVENUE GROWTH GOAL » Double Digit Revenue Growth Full Year 2018 over 2017 » ICL Unit Growth Range 15% to 20% » PROFITABILITY IMPROVEMENT » EPS Improvement Full Year 2018 over 2017 » MAINTAIN & IMPROVE CASH FLOW » Achieve Full Year Positive Cash Flow » Cash Balance Impro
Slide 13: 2018 Financial Outlook: Assumptions
™ ™ 2018 FINANCIAL OUTLOOK » SALES ASSUMPTIONS » Strong Growth Continues in China » Korea Resumes Sales Growth » TICL Approval in U.S. by Year - End » Continuing Favorable Mix of Toric ICL’s Balancing Mid - Diopter Range ICL’s ASP’s » GROSS MARGIN ASSUMPTION » Gross Margin Increase Full Year 2018 ov
Slide 14: ™ ▪ “Millions of Eyes” Global Opportunity – Myopia & Presbyopia ▪ Revenue Growth
™ ▪ “Millions of Eyes” Global Opportunity – Myopia & Presbyopia ▪ Revenue Growth Goal 15% – 20% Annually with Open U.S. Market ▪ Targeting Achievement of Sustained Profitability ▪ Gross Margin & Cash Generation Growth Continues ▪ EVO ICL Product Family Expansion: Myopia & Presbyopia EDOF ▪ Growing G
Slide 15: A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses
A Leading Developer, Manufacturer and Marketer of Premium Implantable Lenses for Refractive Vision Correction Investor Update NASDAQ : STAA January 8, 2018 Evolution in Visual Freedom ™ 15
Staar Surgical — Investor Presentation (January 2018) on 6ix